- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Circulating tumor cells (CTCs), shed into the blood stream by tumors, are thought to provide a means of detecting cancer early, conducting a preliminary assessment of which anticancer agents might prove most effective at treating a given patient, and assessing whether a chosen therapy is working. But, to realize that potential, it is first necessary to detect and trap these rare cells in a fast, efficient, and reliable manner—something that researchers are getting close to accomplishing. In fact, a new research paper from investigators at Emory and Georgia Tech, published in the journal Cancer Research, highlights one promising method that uses gold nanoparticles to detect the presence of CTCs in human blood samples.
One challenge with detecting CTCs is separating out signals from white blood cells, which are similarly sized as tumor cells and can stick to the same antibodies normally used to identify tumor cells. Commercially available devices trap CTCs using antibody-coated magnetic beads, and technicians must stain the trapped cells with several antibodies to avoid falsely identifying white blood cells as tumor cells.
The Emory and Georgia Tech team, led by Dr. Shuming Nie and Dr. Dong Shin, have now shown that polymer-coated and dye-studded gold particles, directly linked to a growth factor peptide rather than an antibody, can detect circulating tumor cells in the blood of patients with head and neck cancer.
"The key technological advance here is our finding that polymer-coated gold nanoparticles that are conjugated with low molecular weight peptides such as EGF [epidermal growth factor] are much less sticky than particles conjugated to whole antibodies," said Nie. "This effect has led to a major improvement in discriminating tumor cells from non-tumor cells in the blood."
EGF binds to the epithelial growth factor receptor (EGFR) that is over-produced on the surfaces of several types of tumor cells.
Upon laser illumination, the particles display a sharp fingerprint-like pattern that is specific to the dye, because the gold enhances the signal coming from the dyes. These results suggests that several types of nanoparticles, each designed to bind to a specific tumor-related molecular marker, could be combined to gain more information about the growth characteristics of the tumor cells. In addition, measuring CTC levels may be sensitive enough to distinguish patients with localized disease from those with metastatic disease.
"Nanoparticles could be instrumental in modifying the process so that circulating tumor cells can be detected without separating the tumor cells from normal blood cells," Nie said. "We've demonstrated that one tumor cell out of approximately one to ten million normal cells can be detected this way."
In collaboration with oncologists at Winship Cancer Institute, the Emory and Georgia Tech team used their nanoparticles to test for CTCs in blood samples from 19 patients with head and neck cancer. Of these patients, 17 had positive signals for CTCs in their blood. The two with low signals were verified to have no circulating cells using a different CTC-detection technique.
"Although the results have not been compared or validated with current CTC detection methods, our 'one-tube' SERS technology could be faster and lower in costs than other detection methods," said Shin, who is the director of the Winship Cancer Institute Chemoprevention Program. "We need to validate this pilot study by continuing with larger groups of patients and comparing with other tests."
About The National Cancer Institute (NCI)
The NCI Alliance for Nanotechnology in Cancer is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat, and prevent cancer. Through its programs and initiatives, the Alliance is committed to building a community of researchers dedicated to using nanotechnology to advance the fight against cancer.
As part of the Center for Strategic Scientific Initiatives, the Alliance for Nanotechnology in Cancer works in concert with other NCI advanced technology initiatives to provide the scientific foundation and team science that is required to transform cancer research and care.
For more information, please click here
National Cancer Institute
Center for Strategic Scientific Initiatives
NCI Office of Cancer Nanotechnology Research (OCNR)
Building 31, Room 10A52
31 Center Drive, MSC 2580
Bethesda, MD 20892-2580
Telephone: (301) 451-8983
Copyright © The National Cancer Institute (NCI)If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
Clues to inner atomic life from subtle light-emission shifts: Hyperfine structure of light absorption by short-lived cadmium atom isotopes reveals characteristics of the nucleus that matter for high precision detection methods July 3rd, 2015